Psilocybin - Braxia Scientific
Alternative Names: Psilocybin- Braxia ScientificLatest Information Update: 08 Aug 2023
At a glance
- Originator Braxia Scientific
- Class Analgesics; Anti-infectives; Anti-inflammatories; Antidepressants; Antineoplastics; Antipsychotics; Anxiolytics; Behavioural disorder therapies; Dimethylamines; Drug withdrawal therapies; Indoles; Mood stabilisers; Neuropsychotherapeutics; Organophosphorus compounds; Phytotherapies; Small molecules
- Mechanism of Action ATP-binding cassette transporter modulators; Serotonin 5-HT2A receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Depressive disorders
Most Recent Events
- 22 Jul 2023 Braxia Scientific completes a phase II trials in Depressive disorders in Canada (unspecified route) (NCT05029466)
- 02 Dec 2022 Braxia completes enrolment in its Phase II- clinical trials in Depressive disorders in Canada (unspecified route)
- 29 Aug 2022 Health Canada approves multiple Special Access Program (SPA) applications to provide psilocybin-assisted psychotherapy for major depressive disorder prior to August 2022